+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 0 - 5Years
All Genders
ID07640984

Global Phase III Study Evaluating JR-446 Safety, Tolerability, and Effects in Children Under 6 with Mucopolysaccharidosis Type IIIB

Led by JCR Pharmaceuticals Co., Ltd. · Updated on 2026-09-21

12

Participants Needed

5

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating JR-446 in children younger than 6 years with Mucopolysaccharidosis Type IIIB MPS IIIB, a rare genetic disorder. This global, open-label Phase III trial aims to assess the safety and tolerability of JR-446, understand its biological effects, and explore early signs of clinical impact on outcomes related to the disease. Participants receive JR-446 through intravenous infusion. The study involves repeated dosing over up to one year. The trial focuses on measuring changes in biological markers found in cerebrospinal fluid, serum, and urine, as well as assessing cognitive function and brain imaging results. Growth measurements such as height, weight, and body mass index are also tracked using standard child growth charts. During the study, participants have multiple visits for safety monitoring, laboratory tests, and imaging assessments over the course of up to 1 year. Researchers evaluate safety, tolerability, and changes from baseline in various biomarkers and clinical measures. The study lasts until about September 2028, with careful monitoring throughout the treatment period to understand JR-446s effects and participant well-being.

CONDITIONS

Brief Title

A Phase I/II Trial of JR-446 in Mucopolysaccharidosis Type IIIB (MPS IIIB)

Research Team

J

JCR Pharmaceuticals Co., Ltd.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here